slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 76,111-76,140
Pages 3,679
Rows per page 30
Component
76,111-76,140 of 110,355
23
The chart illustrates a bridge from 21,055 M€ in 2022 to 22,802 M€ in 2023.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · ActionLoop · Before After1 hit
26
The table breaks down cash flow from operations, net cash from operating activities, and operating free cash flow.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Action1 hit
28
The 2023 dividend is subject to approval at the Annual General Meeting.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Action1 hit
10
The chart demonstrates tumor volume reduction over time, highlighting the efficacy of the THIO + Atezo combination.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
11
The slide outlines a multi-part clinical trial process from Part A (Safety) through Part B (Efficacy/Dose Selection) to a planned Expansion phase.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
13
Data cut of ongoing study THIO-101 as of 13Nov2023.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
14
The slide uses a specific medical study to justify a change in clinical trial endpoint strategy.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
15
Data cut as of 13Nov2023.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
16
The chart tracks individual patient timelines, including disease progression, partial responses, and study outcomes.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
17
The slide outlines a multi-part clinical trial design (basket/umbrella) for a biotech drug candidate.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
18
The slide presents two line charts showing tumor volume reduction over time, highlighting 100% complete response (CR) and resistance to tumor rechallenge.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
22
The slide outlines a clinical trial process flow involving SCLC and NSCLC patient baskets, immune activation, and subsequent combination therapies leading to a Phase 3 expansion.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
27
The slide uses market cap data to establish valuation benchmarks and cites recent M&A activity as a validation of the sector's value.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Competition1 hit
30
Includes details on options, warrants, and insider ownership percentages.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Product1 hit
11
The slide uses data from a 2022 JNCI study to justify the clinical importance of AA detection sensitivity.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
14
The table compares two distinct clinical trials (ColoFuture and eAArly DETECT) across key performance metrics.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
15
The slide uses two scatter plots to benchmark the company against competitors like Guardant Health, CellMax Life, and Cologuard.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Market Size1 hit
17
Uses a combination of an additive equation for the value prop and a chevron-based timeline for the life cycle management.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
20
Uses a chevron-based process flow to represent maturity stages.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
07
The chart compares quarterly container volumes between 2022 and 2023.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit
08
The chart compares 2022 vs 2023 quarterly container volumes.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit
03
The slide uses a three-column layout to summarize technology, market leadership, and business model.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations 1 hit
04
The slide uses a dual-track timeline (Cell Therapy and Drug Discovery) to show company evolution.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations 1 hit
07
The slide uses a process flow diagram to show the funnel from potential partnerships to active clinical programs.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
12
The slide uses a wave-based metaphor to represent sequential growth phases of partner programs.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
03
The slide uses a matrix-like structure to compare financial metrics over time, with donut charts for mix and tables for assets/ROTCE.Morgan Stanley | Investor Presentation Deck | 13 slides · Morgan Stanley
Conference presentation Investor relations Beat · What Is1 hit
06
The slide uses a Gantt-style layout to map clinical phases to specific time periods.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Loop · Golden Circle1 hit
08
The slide uses a standard comparison table format to contrast a competitor (Resmetirom) with the company's own asset (DA-1241).NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
12
The slide presents 10 distinct bar charts comparing Control, DA, DA+DPP4i, and DPP4i groups, with statistical significance markers.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit